Keystone Financial Group (Kentucky)’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

Keystone Financial Group (Kentucky)’s Portfolio PSTX Stock Details PSTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-15,000	Closed	-$42.9K	–	407
2024 Q3	$42.9K	Hold	15,000	–	–	0.01%	370
2024 Q2	$43.8K	Hold	15,000	–	–	0.02%	164
2024 Q1	$47.9K	Hold	15,000	–	–	0.01%	345
2023 Q4	$50.4K	Hold	15,000	–	–	0.01%	296
2023 Q3	$35.7K	Buy	+15,000	New	+$31.4K	0.01%	299

Other funds holding PSTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Keystone Financial Group (Kentucky)'s PSTX Position: Q4 2024 in Review

Keystone Financial Group (Kentucky) sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q4 2024, closing a stake of 15,000 shares — an estimated $42.9K sold.

Keystone Financial Group (Kentucky) first reported a position in PSTX in Q3 2023 and held it in 5 quarters. The position peaked at $50.4K in Q4 2023. 115 funds tracked by Wall St. Rank hold PSTX as of Q4 2024.

Keystone Financial Group (Kentucky) reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
Keystone Financial Group (Kentucky) sold 15,000 Poseida Therapeutics, Inc. Common Stock shares in Q4 2024, an estimated $42.9K.
Keystone Financial Group (Kentucky) first reported a position in Poseida Therapeutics, Inc. Common Stock in Q3 2023 and held it in 5 quarters.
Keystone Financial Group (Kentucky)'s Poseida Therapeutics, Inc. Common Stock position peaked at $50.4K in Q4 2023.
115 funds tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q4 2024.

Based on Keystone Financial Group (Kentucky)'s 13F filing for Q4 2024, filed 13 Feb 2025.